Response

Affiliations

¹ Affiliations of authors: Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY (IGG); University of Texas MD Anderson Cancer Center, Houston, TX (MIH); Amgen Inc., Thousand Oaks, CA (RKJ). glezermi@mskcc.org.
² Affiliations of authors: Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY (IGG); University of Texas MD Anderson Cancer Center, Houston, TX (MIH); Amgen Inc., Thousand Oaks, CA (RKJ).

Comment

Ilya G Glezerman et al. J Natl Cancer Inst. 2014.

. 2014 Jun 6;106(7):dju138.

doi: 10.1093/jnci/dju138. Print 2014 Jul.

¹ Affiliations of authors: Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY (IGG); University of Texas MD Anderson Cancer Center, Houston, TX (MIH); Amgen Inc., Thousand Oaks, CA (RKJ). glezermi@mskcc.org.
² Affiliations of authors: Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY (IGG); University of Texas MD Anderson Cancer Center, Houston, TX (MIH); Amgen Inc., Thousand Oaks, CA (RKJ).

No abstract available

Comment on

Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Hu MI, et al. J Natl Cancer Inst. 2013 Sep 18;105(18):1417-20. doi: 10.1093/jnci/djt225. Epub 2013 Aug 29. J Natl Cancer Inst. 2013. PMID: 23990665 Free PMC article. Clinical Trial.
Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Tsuda M, Ishiguro H, Yano I, Toi M. Tsuda M, et al. J Natl Cancer Inst. 2014 Jun 6;106(7):dju137. doi: 10.1093/jnci/dju137. Print 2014 Jul. J Natl Cancer Inst. 2014. PMID: 24906398 No abstract available.